BioPharm International Supplements, October 2008 - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

BioPharm International Supplements, October 2008
Articles
Developing Plasmid DNA Vaccines
Interview with Magda Marquet, co-CEO and co-president of Althea Technologies
Formulation Studies of an Adsorbed Conjugate Vaccine
By Shwu-Maan Lee, PhD , Chris Donaldson
NeisVac-C is a polysaccharide-protein conjugate vaccine for use against Neisseria meningitidis serogroup C infection. The Phase 1 clinical formulation consisted of physiological saline, thimerosal, and aluminum hydroxide. The long-term stability data for both the PBS and saline formulations are presented in this article.
Bridging the Gap in Translational Research for Vaccines
Interview with Roger Lias, president and group commercial director at Eden Biodesign, Inc.
Manufacturing Process Development for an Epidermal Growth Factor-Based Cancer Vaccine
By Gryssell Rodriguez , Airama Albisa , Lisel Viņa , Ariadna Cuevas , Beatriz Garcia , Aurora Tamara Garcia , Alejandro Portillo , Loany Calvo , Tania Crombet , Gisela Gonzalez , Ernesto Chico
The Center for Molecular Immunology (Havana, Cuba) has been working on a novel cancer immunotherapy targeting the epidermal growth factor (EGF). The vaccine is composed of a chemical conjugate of EGF and a carrier protein (rP64k), designed to trigger an anti-EGF antibody response. The results of studies of molecular characterization, immunogenic activity, and clinical data are presented here.
Vaccines Incorporating Toll-Like Receptor Ligands
By Alan Shaw, PhD
This article discusses the production process of the major influenza antigen, hemagglutinin (HA), by rDNA methods in E. coli.
Preparedness for Pandemic Flu Outbreak
By Bikash Chatterjee
To succeed in a pandemic, the industry must forge a preparedness plan to ensure adequate vaccines.
Developing and Manufacturing Attenuated Live Bacterial Vaccines
By Guido Dietrich , Andre Collioud , Simon A. Rothen
There are a number of specific characteristics to be considered when developing and manufacturing live bacterial vaccines.

ADVERTISEMENT

ADVERTISEMENT

Click here